Instead of admitting that it has, in the past, sold food with too much sodium, salt and sugar, Walmart (NYSE: WMT) has made a public relations bonanza of its decision ... Read Full Story »
Pfizer Inc. (NYSE: PFE) has a big day ahead of it. While it has been known for years, it is a massive date: Lipitor goes off-patent and will have generic ... Read Full Story »
There is an old rule of thumb from biotech investors and traders... SELL FDA APPROVALS. This is very counter-intuitive on the surface but we wanted to explain in more detail ... Read Full Story »
If you have seen the graphic images that will go on cigarette packages late in 2011, you might think that the tobacco companies have finally met their match. The graphic ... Read Full Story »
If Altria Group Inc. (NYSE: MO), Reynolds American Inc. (NYSE: RAI), Anheuser-Busch InBev (NYSE: BUD), and Molson Coors Brewing Company (NYSE: TAP) should keep an eye on efforts to legalize ... Read Full Story »
The FDA is about to give some serious warning labels on cigarette labels. Altria Group Inc. (NYSE: MO), Reynolds American Inc. (NYSE: RAI), Lorillard, Inc. (NYSE: LO) and Vector Group ... Read Full Story »
Cell Therapeutics, Inc. (NASDAQ: CTICD) has been very active since its recent 1-for-6 reverse stock split took place on May 16, 2011. Its share volume has increased on all but ... Read Full Story »
This last week marked another solid week for investors and many stocks were on the move. We have compiled a list of stocks we are looking for event-driven trading moves ... Read Full Story »
When we first covered K-V Pharmaceutical Co. (NYSE: KV-A) for its Makena drug market exclusivity to prevent premature birth, we knew this was going to be a home run. But ... Read Full Story »
The fight against melanoma just got a new weapon after a drug called Yervoy, or ipilimumab, was given FDA approval for late-stage metastatic melanoma. The approval is a win for ... Read Full Story »
2010 is ending and 2011 is about to begin. It has been a very interesting year for major biotech stocks, albeit with lower rewards than seen in 2009 as there ... Read Full Story »
2010 has been an interesting year in biotech and in biohealth stocks, even if it has lacked some of the ten-baggers that were seen in 2009. In 2009, companies like ... Read Full Story »
The world of biotech and biohealth is seeing a flurry of news today. This is bringing on many winners and losers in the sector. We are tracking the news and ... Read Full Story »
Stem cell stocks are getting hit pretty hard this Tuesday. On Monday came a ruling from a U.S. district judge which effectively blocks the federal government from funding research which ... Read Full Story »
There are many issues to watch in the coming week for this weekend's edition of THE UNUSUAL SUSPECTS. We have some earnings on deck and some unfinished business from last ... Read Full Story »